Literature DB >> 3205383

Injection of L-allylglycine into the posterior hypothalamus in rats causes decreases in local GABA which correlate with increases in heart rate.

V M Abshire1, K D Hankins, K E Roehr, J A DiMicco.   

Abstract

Injection of the GABA antagonist, bicuculline methiodide into the posterior hypothalamus of rats has been shown to cause marked increases in heart rate and lesser elevations in blood pressure. Allylglycine is a potent inhibitor of the synthetic enzyme for GABA, glutamic acid decarboxylase, only after in vivo biotransformation into its active form, 2-keto-4-pentenoic acid, through a stereospecific amino acid oxidase. The posterior hypothalamus is thought to contain substantial activity only of L-amino acid oxidase. In this study, the stereoisomers of allylglycine were injected into the posterior hypothalamus at a site also shown to be reactive to bicuculline. Injection of L-allylglycine but not D-allylglycine caused substantial increases in heart rate but only slight increases in blood pressure. Injection of the GABA agonist muscimol prior to treatment with L-allylglycine prevented these cardiovascular changes. In another series of experiments, levels of GABA in the posterior hypothalamus and adjacent areas were measured 90 min after unilateral injection of L-allylglycine (12.5 or 25 micrograms), D-allylglycine (25 micrograms) or saline into the posterior hypothalamus. Only L-allylglycine caused increases in heart rate and blood pressure and decreases in levels of GABA. Quantitatively, the increases in heart rate at sacrifice were strongly correlated with the decreases in levels of GABA in the injected posterior hypothalamus (r = -0.94; P less than 0.002) but not in other regions.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3205383     DOI: 10.1016/0028-3908(88)90013-5

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

1.  Time course of effects of 3-mercaptopropionic acid on GABA levels in different brain regions in guinea pigs: possible relationship with associated cardiovascular changes.

Authors:  N L Alsip; J A DiMicco
Journal:  Neurochem Res       Date:  1992-05       Impact factor: 3.996

2.  A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects.

Authors:  Pascal Bonaventure; Sujin Yun; Philip L Johnson; Anantha Shekhar; Stephanie D Fitz; Brock T Shireman; Terry P Lebold; Diane Nepomuceno; Brian Lord; Michelle Wennerholm; Jonathan Shelton; Nicholas Carruthers; Timothy Lovenberg; Christine Dugovic
Journal:  J Pharmacol Exp Ther       Date:  2015-01-12       Impact factor: 4.030

Review 3.  Corticolimbic regulation of cardiovascular responses to stress.

Authors:  Brent Myers
Journal:  Physiol Behav       Date:  2016-10-25

4.  Changes in central sodium and not osmolarity or lactate induce panic-like responses in a model of panic disorder.

Authors:  Andre I Molosh; Philip L Johnson; Stephanie D Fitz; Joseph A Dimicco; James P Herman; Anantha Shekhar
Journal:  Neuropsychopharmacology       Date:  2010-02-03       Impact factor: 7.853

5.  Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats.

Authors:  Philip L Johnson; Stephanie D Fitz; Eric A Engleman; Kjell A Svensson; Jeffrey M Schkeryantz; Anantha Shekhar
Journal:  J Psychopharmacol       Date:  2012-08-21       Impact factor: 4.153

6.  Neural pathways underlying lactate-induced panic.

Authors:  Philip L Johnson; William A Truitt; Stephanie D Fitz; Christopher A Lowry; Anantha Shekhar
Journal:  Neuropsychopharmacology       Date:  2007-12-05       Impact factor: 7.853

7.  Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation.

Authors:  Pascal Bonaventure; Christine Dugovic; Brock Shireman; Cathy Preville; Sujin Yun; Brian Lord; Diane Nepomuceno; Michelle Wennerholm; Timothy Lovenberg; Nicolas Carruthers; Stephanie D Fitz; Anantha Shekhar; Philip L Johnson
Journal:  Front Pharmacol       Date:  2017-06-09       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.